Skip to contentB
Bone Biologics Corp
B
BBLGBone Biologics Corp Q3 2021 · 10-Q
Revenue—
Net Income-$509.30K-$509.30KN/M vs Q3 2020 EPS Diluted-$0.17-$0.17N/M vs Q3 2020 Operating Income-$229,789N/M Operating Cash Flowderived-$277,770N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bone Biologics Corp · CIK 1419554 · Engraved from SEC EDGAR
ended Sep 30, 2021 · filed Nov 15, 2021 · 46 d after period end